Inside Asia’s biohacking landscape: the science, trends and scientists to know

The rise of biohacking is partly a technology story. Wearables made sleep, heart rate and recovery visible. Continuous glucose monitors (CGMs) made blood sugar patterns available in real time. Apps, rings, watches and dashboards helped create a new expectation: that the body should produce data, and that data should lead to action.

The popularity of biohacking is also cultural. Ageing science has made longevity feel more modifiable. Social media has turned health routines into “protocols”. The pandemic sharpened interest in prevention, immunity and resilience. Affluent wellness consumers increasingly expect more than relaxation from their spending. They want tests, biomarkers, personalisation and measurable results.

This is where the term becomes slippery. Some practices are simply proven health habits in new language, while others are medical interventions repackaged as wellness. Some are promising but early, while some are commercial claims dressed in scientific vocabulary.

Read more: Matthew Walker on why the most productive thing we can all do is sleep

The least glamorous side of biohacking is also the most defensible. Factors like sleep, exercise, strength, metabolic health, nutrition, stress regulation, recovery, blood pressure control, routine screening and social connection are not new. But they also have stronger evidence than much of what is marketed as advanced optimisation.

Newer tools can still be useful. A wearable may help someone notice poor sleep. A continuous glucose monitor may show how food, stress, sleep and exercise affect blood sugar levels. A biomarker panel may surface risks worth discussing with a doctor. The issue isn’t the measurement itself. The issue is whether knowing all this about your body leads to better judgement or if it’s just making you become more anxious.

In the promising but early category are some forms of personalised biomarker tracking, selected uses of CGMs, heat and cold exposure, and serious research into longevity compounds. In the limited or mixed category are many consumer biological age tests, supplement stacks and nootropics. In the experimental or commercial-claim category are many stem cell, exosome, peptide, IV and regenerative offerings marketed directly to consumers.

It is important to remain critical, because biohacking culture often flattens evidence. A walk after dinner and an exosome infusion can appear in the same feed under the same promise of optimisation, but the research behind each of them differs.

Asia is ageing quickly. The United Nations Population Fund (UNFPA) projects that by 2050, one in four people in Asia and the Pacific will be over 60, with the region’s older population reaching close to 1.3 billion. The World Health Organisation’s Southeast Asia office says the share of people aged 60 and above in the region is expected to rise from 12.2 per cent in 2024 to 22.9 per cent by 2050, and notes that longer life is not always accompanied by good health.

That gives biohacking in Asia a different urgency. The subject is not only about helping high performers sleep better or lowering biological age. It is also about healthspan, chronic disease, frailty, prevention, caregiving, family structures, medical costs and how people can remain functional for longer.

At the same time, Asia’s wellness market is expanding. The Global Wellness Institute has described Asia Pacific as a US$2 trillion wellness market, while noting that Asia’s wellness tourism market reached US$215 billion and grew 31 per cent in 2024.

Affluent consumers are spending on diagnostics, longevity clinics, wearable data, aesthetics, recovery therapies, supplements, medical-wellness retreats and preventive care—but underneath this commercial aspect is a larger public-health question. In Asia, biohacking exists on two levels: a societal need to extend healthy life, and a premium consumer market trying to buy more control over the body.

Metabolic tracking is one of the trend’s most obvious expressions. Globally, CGMs have moved into conversations about blood sugar, energy, food sequencing, exercise timing and metabolic health. In Asia, this overlaps with concern around diabetes and cardiometabolic disease, as well as growing demand for wearable health data. 

Thailand gives the story its medical-wellness and hospitality angle. Bumrungrad’s VitalLife Scientific Wellness Center positions itself around functional and anti-ageing medicine, with longevity as a central promise. RAKxa, near Bangkok, offers an integrative longevity program that combines lab diagnostics with Thai, Chinese and Ayurvedic medicine. This is where biohacking becomes an experience: a retreat, a diagnostic program, a recovery protocol, a week of testing and treatments. 

Singapore offers a more scientific and clinical answer to the question. As a regional hub for longevity research and AI-enabled medicine, it has become a place where ageing is increasingly approached through biology, data and medical oversight.

The National University of Singapore (NUS) is an example of an institution moving the needle, with work spanning the biology of ageing and the development of Curate.AI, an AI platform designed to help optimise treatment using patient data.

Read more: Youthful ageing: longevity expert Professor Andrea Maier wants to live better, not necessarily longer

South Korea offers another regional variation: biohacking as skin longevity and aesthetic maintenance, not just performance optimisation. Korean medical tourism is strongly tied to dermatology, injectables, lasers and non-invasive skin treatments. Reuters reported that South Korea surpassed two million foreign patients in 2025, with demand partly driven by treatments such as Botox, red-light therapy and ultrasound skin lifting; Korean government reporting put the figure at 2.01 million foreign patients.

Japan brings a more institutional anti-ageing medicine context, via formal professional structures around anti-ageing medicine, prevention and healthy lifespan. Then known as the Academy of Anti-Ageing Medicine Japan, the Japanese Society of Anti-Aging Medicine began in 2001 and now has more than 8,000 members across basic research and clinical specialties. 

Singapore, China and Hong Kong sit closer to the AI-biotech side of the map. Biotech companies like the US-based Insilico Medicine—which describes its mission as extending healthy productive longevity by transforming drug discovery and development with generative AI—has facilities in Hong Kong. Singapore-based Gero describes its work as using physics and data science at the intersection of AI and human health to address ageing and complex disease. This is biohacking at the bleeding edge of computational biology, drug discovery, biomarkers and ageing research.

Read more: Forget the silver bullet: inside Dan Buettner’s Blue Zones blueprint for a longer life

Then there is traditional medicine, the most delicate Asian thread. Traditional Chinese medicine, Ayurveda, Kampo, Korean traditional medicine, Thai healing and other systems have long dealt with diet, herbs, breath, movement, sleep, heat, seasonality and individualised care. This may not be biohacking in the Instagram era, but it shows that personalised prevention and wellness is already ancient practice.

WHO established its Global Traditional Medicine Centre in India in 2022 with support from the Government of India, with a mandate to support evidence, policies and standards for traditional medicine. That intersection of old and new is a very useful line of inquiry: science isn’t interested in whether older health systems can be rebranded as biohacking, but it is interested in finding out which practices can be studied, standardised and responsibly integrated.

The most useful biohacking guide may be less about what to try and more about what to question.

Biological age tests are a good example. Ageing clocks use machine learning to estimate biological age as a proxy for general health, but a 2025 review in the journal NPJ Aging highlighted challenges including abstract definitions, inconsistent clinical validation and uncertainty in prediction. So while these tests may be interesting, they should not be treated as a definitive verdict.

Nicotinamide adenine dinucleotide (NAD) use is another case. NAD-related supplements and IV treatments are heavily marketed for energy and anti-ageing. A 2026 review found biological activity, but said clinical effectiveness for anti-ageing or wellness outcomes remains inconclusive. 

Read more: Longevity’s most-used words, decoded

Rapamycin and metformin sit are backed by science, but still require care. Rapamycin has generated interest because of ageing biology and animal research, yet human longevity evidence remains nuanced and context-dependent. Metformin is being studied through the Targeting Ageing with Metformin, or TAME. This large-scale trial is designed to test whether the drug can delay the development or progression of age-related chronic diseases. It is important science, but it shouldn’t be treated as a casual prescription.

Regenerative medicine deserves firmer caution. Stem cells and exosomes appear frequently in anti-ageing, aesthetics and medical-wellness marketing. The US Food and Drug Administration (FDA) warns consumers about regenerative medicine products including stem cells and exosomes, cautioning that there are currently no FDA-approved exosome products.

GLP-1 medications—which include Ozempic, Wegovy, Mounjaro and the like—also belong in the wider biohacking conversation because they have played a significant role in metabolic health, weight loss and body-composition culture. But they are prescription drugs, not wellness accessories. In 2026, the FDA warned about fraudulent compounded semaglutide and tirzepatide products marketed for weight loss, including products with false label information and pharmacies that did not exist.

Unfortunately, this follows the same patterns as many other wellness trends: biohacking often borrows from legitimate science before the consumer market has caught up with evidence, regulation or clinical supervision. That does not mean that we can dismiss the entire field—it just means that we should ask better questions.

Read more: Peptides are everywhere in wellness. How much of the promise is backed by evidence?

The most important Asian players in biohacking are the scientists, clinicians, founders, institutions, clinics and platforms.

Geroscience professor Andrea Maier is one of the most visible names in Asia’s longevity medicine ecosystem. She co-founded and directs the NUS Academy for Healthy Longevity and also co-founded Chi Longevity, a Singapore-based longevity clinic focused on translating ageing science into clinical practice. She has more than 500 peer-reviewed publications.

Ageing researcher Brian Kennedy’s work explores the biology of ageing and how basic discoveries can be translated into strategies to delay, detect, prevent and treat age-related disease. His research connected to cellular pathways such as sirtuins and mTOR. 

AI-medicine researcher and professor Dean Ho is known for advancing patient-specific, data-driven personalisation in medicine. As director of the NUS Institute for Digital Medicine, he has helped develop Curate.AI, an AI platform that uses a patient’s own treatment-response data to refine dosing over time, with applications studied in oncology and other clinical areas.

Gerophysics founder Peter Fedichev is CEO and co-founder of Gero, an AI-driven ageing biotech company associated with Singapore. Gero uses real-world human data, physics and AI to model aging trajectories and identify biological pathways linked to age-related disease.

Entrepreneur Danny Yeung is co-founder and CEO of Prenetics, the Hong Kong-founded health sciences company that began in genetics and diagnostics and has expanded into prevention, early detection and personalised care. His work shows how consumer diagnostics and longevity-adjacent health services are being commercialised in Asia.

Molecular diagnostics scientist Dennis Lo gives the Hong Kong diagnostics story its scientific depth. A Chinese University of Hong Kong (CUHK) professor known for pioneering work in circulating cell-free DNA and non-invasive prenatal testing, Lo co-founded Insighta with Yeung to develop multi-cancer early detection screening through blood-based diagnostics.

Read more: Prenetics’ Danny Yeung and Dennis Lo launch Insighta, an early cancer detection testing company

Health-tech founders Mohit Kumar and Vatsal Singhal are the co-founders of Ultrahuman, the India-based self-quantification company behind the Ultrahuman Ring, M1 continuous glucose monitoring platform and related blood, sleep, recovery and metabolic tracking tools. Ultrahuman shows Asia producing its own consumer biohacking platforms, not simply importing from the West.

AI-diagnostics founder Kevin Taegeun Choi is co-founder and CEO of Mediwhale, a Seoul-based digital health company using AI-driven retinal imaging to assess cardiovascular, kidney and eye disease risk, pushing the optimisation conversation toward medical-grade prediction.

Regenerative-medicine scientist Shinya Yamanaka should be included as a serious counterpoint to loose stem-cell marketing. Based at Kyoto University’s Center for iPS Cell Research and Application, he won the 2012 Nobel Prize in Physiology or Medicine for discovering that mature cells can be reprogrammed to become pluripotent, work that underpins major areas of regenerative medicine and drug discovery.

Ageing biologist Seung-Jae V Lee gives South Korea more scientific depth beyond aesthetics and medical tourism. A Korea Advanced Institute of Science and Technology (KAIST) professor, he has led research into ageing mechanisms including circular RNA, with KAIST reporting work on RNASEK as a regulator that may slow ageing and support healthy longevity in model systems.

Together, these names form an interesting longevity picture of the region: Singapore’s longevity and AI-medicine ecosystem; Hong Kong’s genomics and early-detection companies; India’s consumer health-tech platforms; Korea’s AI diagnostics and ageing biology; Japan’s anti-ageing and regenerative medicine infrastructure; and Thailand’s medical-wellness market. Asia’s longevity story, in other words, is still being written by several hands at once.

NOW READ

Youthful ageing: longevity expert Professor Andrea Maier wants to live better, not necesarily longer

As part of the Belt and Road initiative, China’s biotech boom transforms global markets

How one man’s stress and burnout led to Manila’s first social biohacking club